Charles Jakielaszek

473 total citations
12 papers, 326 citations indexed

About

Charles Jakielaszek is a scholar working on Molecular Medicine, Molecular Biology and Epidemiology. According to data from OpenAlex, Charles Jakielaszek has authored 12 papers receiving a total of 326 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Medicine, 4 papers in Molecular Biology and 4 papers in Epidemiology. Recurrent topics in Charles Jakielaszek's work include Antibiotic Resistance in Bacteria (5 papers), Antibiotics Pharmacokinetics and Efficacy (3 papers) and Urinary Tract Infections Management (2 papers). Charles Jakielaszek is often cited by papers focused on Antibiotic Resistance in Bacteria (5 papers), Antibiotics Pharmacokinetics and Efficacy (3 papers) and Urinary Tract Infections Management (2 papers). Charles Jakielaszek collaborates with scholars based in United States, United Kingdom and Australia. Charles Jakielaszek's co-authors include Nicole E. Scangarella-Oman, D.F. Sahm, Douglas J. Biedenbach, S. Bouchillon, Linda A. Miller, Meredith Hackel, Brian Wynne, M. J. Flynn, Hannah M. Wexler and M. McTeague and has published in prestigious journals such as The Lancet, Clinical Infectious Diseases and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Charles Jakielaszek

12 papers receiving 312 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Charles Jakielaszek United States	8	122	94	86	59	58	12	326
Hiroyuki Kobayashi Japan	11	170 1.4×	82 0.9×	113 1.3×	14 0.2×	42 0.7×	28	427
MARY MANOUSOS United States	7	115 0.9×	115 1.2×	184 2.1×	15 0.3×	121 2.1×	9	472
Rolf Troller Switzerland	14	55 0.5×	117 1.2×	292 3.4×	26 0.4×	16 0.3×	17	442
Lisa M. Karenchak United States	12	60 0.5×	79 0.8×	53 0.6×	8 0.1×	232 4.0×	18	900
Elisa Marchionni Italy	9	45 0.4×	67 0.7×	144 1.7×	19 0.3×	60 1.0×	14	303
Jane Democratis United Kingdom	10	90 0.7×	20 0.2×	330 3.8×	32 0.5×	13 0.2×	12	465
Rinya Sugita Japan	11	25 0.2×	32 0.3×	196 2.3×	102 1.7×	24 0.4×	63	352
Bernard Boisramé Switzerland	12	41 0.3×	142 1.5×	108 1.3×	9 0.2×	298 5.1×	16	521
Nai‐Xun Chin United States	11	50 0.4×	146 1.6×	183 2.1×	8 0.1×	153 2.6×	26	388
Rosemol Varghese India	11	42 0.3×	71 0.8×	225 2.6×	7 0.1×	34 0.6×	25	352

Countries citing papers authored by Charles Jakielaszek

Since Specialization

Citations

This map shows the geographic impact of Charles Jakielaszek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles Jakielaszek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles Jakielaszek more than expected).

Fields of papers citing papers by Charles Jakielaszek

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles Jakielaszek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles Jakielaszek. The network helps show where Charles Jakielaszek may publish in the future.

Co-authorship network of co-authors of Charles Jakielaszek

This figure shows the co-authorship network connecting the top 25 collaborators of Charles Jakielaszek. A scholar is included among the top collaborators of Charles Jakielaszek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles Jakielaszek. Charles Jakielaszek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Ross, Jonathan, Kimberly Workowski, Stephanie N. Taylor, et al.. (2025). Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): a phase 3 randomised, open-label, non-inferiority, multicentre study. The Lancet. 405(10489). 1608–1620. 11 indexed citations

Hilliard, Jamese J., Charles Jakielaszek, Frank Mannino, et al.. (2024). Efficacy of therapeutically administered gepotidacin in a rabbit model of inhalational anthrax. Antimicrobial Agents and Chemotherapy. 68(3). e0149723–e0149723. 2 indexed citations

Perry, Caroline, Nicole E. Scangarella-Oman, Helen Millns, et al.. (2023). Efficacy and Safety of Gepotidacin as Treatment of Uncomplicated Urogenital Gonorrhea (EAGLE-1): Design of a Randomized, Comparator-Controlled, Phase 3 Study. Infectious Diseases and Therapy. 12(9). 2307–2320. 16 indexed citations

Jakielaszek, Charles, Jamese J. Hilliard, Frank Mannino, et al.. (2023). Efficacy of Intravenously Administered Gepotidacin in Cynomolgus Macaques following a Francisella tularensis Inhalational Challenge. Antimicrobial Agents and Chemotherapy. 67(5). e0138122–e0138122. 6 indexed citations

Jakielaszek, Charles, Mohammad Sharif Hossain, Lian Qian, et al.. (2022). Gepotidacin is efficacious in a nonhuman primate model of pneumonic plague. Science Translational Medicine. 14(647). eabg1787–eabg1787. 9 indexed citations

Biedenbach, Douglas J., S. Bouchillon, Meredith Hackel, et al.. (2016). In Vitro Activity of Gepotidacin, a Novel Triazaacenaphthylene Bacterial Topoisomerase Inhibitor, against a Broad Spectrum of Bacterial Pathogens. Antimicrobial Agents and Chemotherapy. 60(3). 1918–1923. 97 indexed citations

Tsuji, Masakatsu, et al.. (2016). S-649266, a Novel Siderophore Cephalosporin: In Vitro Activity Against Biothreat Pathogen. Open Forum Infectious Diseases. 3(suppl_1). 3 indexed citations

O’Dwyer, Karen, Aaron Spivak, Karen Ingraham, et al.. (2014). Bacterial Resistance to Leucyl-tRNA Synthetase Inhibitor GSK2251052 Develops during Treatment of Complicated Urinary Tract Infections. Antimicrobial Agents and Chemotherapy. 59(1). 289–298. 73 indexed citations

Koeth, Laura, Michael R. Jacobs, Caryn E. Good, et al.. (2004). Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000. International Journal of Infectious Diseases. 8(6). 362–373. 6 indexed citations

10.

Koeth, Laura, et al.. (2004). Streptococcus pneumoniae in vitro development of resistance to amoxicillin/clavulanic acid, cefaclor, levofloxacin and azithromycin. International Journal of Antimicrobial Agents. 24(2). 144–149. 8 indexed citations

11.

Finegold, S M, M. J. Flynn, Hannele Jousimies–Somer, et al.. (2002). Bacteriologic Findings Associated with Chronic Bacterial Maxillary Sinusitis in Adults. Clinical Infectious Diseases. 35(4). 428–433. 84 indexed citations

12.

Jakielaszek, Charles, et al.. (1999). Escherichia coli ATCC 35218 as a Quality Control Isolate for Susceptibility Testing of Haemophilus influenzae with Haemophilus Test Medium. Antimicrobial Agents and Chemotherapy. 43(2). 283–286. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact